EP3897607A4 - Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor - Google Patents
Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor Download PDFInfo
- Publication number
- EP3897607A4 EP3897607A4 EP19901283.2A EP19901283A EP3897607A4 EP 3897607 A4 EP3897607 A4 EP 3897607A4 EP 19901283 A EP19901283 A EP 19901283A EP 3897607 A4 EP3897607 A4 EP 3897607A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- benzylthio
- bis
- compositions
- treating cancer
- octanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- GXDQJPLRORWRMG-UHFFFAOYSA-N 6-benzyl-9-phenylnonanethioic s-acid Chemical compound C=1C=CC=CC=1CC(CCCCC(=O)S)CCCC1=CC=CC=C1 GXDQJPLRORWRMG-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000012822 autophagy inhibitor Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782928P | 2018-12-20 | 2018-12-20 | |
| US201962793667P | 2019-01-17 | 2019-01-17 | |
| US201962834475P | 2019-04-16 | 2019-04-16 | |
| US201962854599P | 2019-05-30 | 2019-05-30 | |
| PCT/US2019/067759 WO2020132397A1 (en) | 2018-12-20 | 2019-12-20 | Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3897607A1 EP3897607A1 (en) | 2021-10-27 |
| EP3897607A4 true EP3897607A4 (en) | 2022-08-24 |
Family
ID=71101607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19901283.2A Withdrawn EP3897607A4 (en) | 2018-12-20 | 2019-12-20 | Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3897607A4 (en) |
| JP (1) | JP2022515171A (en) |
| KR (1) | KR20210105923A (en) |
| CN (1) | CN113543778A (en) |
| AU (1) | AU2019404339A1 (en) |
| CA (1) | CA3121929A1 (en) |
| TW (1) | TW202038931A (en) |
| WO (1) | WO2020132397A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023070101A1 (en) * | 2021-10-22 | 2023-04-27 | Cornerstone Pharmaceuticals, Inc. | Therapeutic methods and compositions for treating cancer using devimistat and a fatty acid oxidation inhibitor, a tyrosine kinase inhibitor, a glutaminase inhibitor, and/or a glycolysis inhibitor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11344620B2 (en) * | 2014-09-13 | 2022-05-31 | Novartis Ag | Combination therapies |
-
2019
- 2019-12-20 WO PCT/US2019/067759 patent/WO2020132397A1/en unknown
- 2019-12-20 CA CA3121929A patent/CA3121929A1/en active Pending
- 2019-12-20 EP EP19901283.2A patent/EP3897607A4/en not_active Withdrawn
- 2019-12-20 CN CN201980084130.9A patent/CN113543778A/en active Pending
- 2019-12-20 AU AU2019404339A patent/AU2019404339A1/en not_active Abandoned
- 2019-12-20 KR KR1020217021086A patent/KR20210105923A/en unknown
- 2019-12-20 TW TW108147080A patent/TW202038931A/en unknown
- 2019-12-20 JP JP2021535902A patent/JP2022515171A/en active Pending
Non-Patent Citations (8)
| Title |
|---|
| ANGELIQUE V ONORATI ET AL: "Targeting autophagy in cancer", CANCER, AMERICAN CANCER SOCIETY , PHILADELPHIA , PA, US, vol. 124, no. 16, 19 April 2018 (2018-04-19), pages 3307 - 3318, XP071177994, ISSN: 0008-543X, DOI: 10.1002/CNCR.31335 * |
| ANONYMOUS: "Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma", BLOOD, 1 January 2016 (2016-01-01), XP055741754, Retrieved from the Internet <URL:https://ashpublications.org/blood/article/128/22/4163/114147/Phase-I-Dose-Escalation-Study-of-Cpi-613-in> [retrieved on 20201020] * |
| KING C LEE ET AL: "Translational assessment of mitochondrial dysfunction of pancreatic cancer from in vitro gene microarray and animal efficacy studies, to early clinical studies, via the novel tumor-specific anti-mitochondrial agent, CPI-613", ANNALS OF TRANSLATIONAL MEDICINE, 1 September 2014 (2014-09-01), China, pages 91 - 1014, XP055679530, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205874/pdf/atm-02-09-91.pdf> [retrieved on 20200325], DOI: 10.3978/j.issn.2305-5839.2014.05.08 * |
| PASQUIER BENOIT: "Autophagy inhibitors", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, vol. 73, no. 5, 11 December 2015 (2015-12-11), pages 985 - 1001, XP035801809, ISSN: 1420-682X, [retrieved on 20151211], DOI: 10.1007/S00018-015-2104-Y * |
| REBECCA ANDERSON BS ET AL: "PHARMACOLOGIC INHIBITION OF CELLULAR METABOLIC PROCESSES IMPACTED BY AGING SENSITIZE ACUTE MYELOID LEUKEMIA CELLS TO THE NOVEL LIPOATE DERIVATIVE CPI-613", HEMASPHERE, 1 June 2018 (2018-06-01), XP055722056, Retrieved from the Internet <URL:https://rafaelpharma.com/wp-content/uploads/2018/07/Rafael-Abstract-EHA-2018-Poster-AML_Aging.pdf> [retrieved on 20200812] * |
| See also references of WO2020132397A1 * |
| T. S. PARDEE ET AL: "A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies", CLINICAL CANCER RESEARCH, vol. 20, no. 20, 27 August 2014 (2014-08-27), US, pages 5255 - 5264, XP055721419, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-14-1019 * |
| ZUZANA ZACHAR ET AL: "Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo", JOURNAL OF MOLECULAR MEDICINE, SPRINGER, BERLIN, DE, vol. 89, no. 11, 19 July 2011 (2011-07-19), pages 1137 - 1148, XP019965329, ISSN: 1432-1440, DOI: 10.1007/S00109-011-0785-8 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019404339A1 (en) | 2021-06-24 |
| CN113543778A (en) | 2021-10-22 |
| TW202038931A (en) | 2020-11-01 |
| CA3121929A1 (en) | 2020-06-25 |
| WO2020132397A1 (en) | 2020-06-25 |
| JP2022515171A (en) | 2022-02-17 |
| EP3897607A1 (en) | 2021-10-27 |
| KR20210105923A (en) | 2021-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3947715A4 (en) | Methods and compositions for treating cancer | |
| EP3894392A4 (en) | Compositions and methods for the treatment of cancer | |
| EP3983445A4 (en) | Compositions and methods for treating cancer | |
| EP3826666A4 (en) | Compositions and methods for treating nrp2-associated diseases | |
| EP3938354A4 (en) | Compositions and methods for treating cancer | |
| EP3934652A4 (en) | Compounds, compositions, and methods for the treatment of disease | |
| EP3934615A4 (en) | Compositions and methods for treating acne | |
| EP3890725A4 (en) | Compositions for treating dermatological diseases | |
| EP3775263A4 (en) | Compositions and methods for the treatment of acne | |
| EP3968785A4 (en) | Compositions and methods for treating cancer | |
| EP3931336A4 (en) | Compositions and methods for treating laminopathies | |
| EP3737379A4 (en) | Compositions and methods for treating metabolic diseases | |
| EP3965896A4 (en) | Compositions and methods for treating cancer | |
| EP3908601A4 (en) | Methods and compositions for treating cancer | |
| EP4085053A4 (en) | Treatment of cancer with cdk12/13 inhibitors | |
| EP3793566A4 (en) | Compositions and methods for reducing spliceopathy and treating rna dominance disorders | |
| EP4003351A4 (en) | Methods and compositions for treating cancer | |
| EP3969597A4 (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| EP3849591A4 (en) | Methods and compositions for treating skin diseases | |
| EP3773585A4 (en) | Compositions and methods for treating cancer | |
| EP4017490A4 (en) | Compounds and methods for treating oxalate-related diseases | |
| EP3781148A4 (en) | Therapeutic methods and compositions for treating prostate cancer using 6,8-bis-benzylthio-octanoic acid | |
| EP3983014A4 (en) | Compositions and methods for treating cancer | |
| EP3897607A4 (en) | Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor | |
| EP3820477A4 (en) | Compounds, compositions, and methods for the treatment of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20210719 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20220722 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20220718BHEP Ipc: A61P 35/02 20060101ALI20220718BHEP Ipc: A61P 35/00 20060101ALI20220718BHEP Ipc: A61K 31/155 20060101ALI20220718BHEP Ipc: A61K 31/7004 20060101ALI20220718BHEP Ipc: A61K 31/4184 20060101ALI20220718BHEP Ipc: A61K 31/4706 20060101ALI20220718BHEP Ipc: A61K 31/20 20060101AFI20220718BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20230221 |